Security key
22663K107
Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX)
CUSIP: 22663K107
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / COMMON STOCK
- Shares outstanding
- 105,000,216
- Total 13F shares
- 122,775,077
- Share change
- +9,904,287
- Total reported value
- $4,457,215,277
- Put/Call ratio
- 105%
- Reported price per share
- $36.32
- Number of holders
- 239
- Value change
- +$303,491,173
- Number of buys
- 156
- Number of sells
- 97
Security identity
2 facts
Holder snapshot
9 facts
Report period
Q1 2026
Institutions
239
Top holders
10
CRNX full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q4 2025
Crinetics Pharmaceuticals, Inc. SEC filings
Crinetics Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 22663K107
Recent filing periods:
Ownership snapshot
Top reported holders of CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
FMR LLC
13D/G signal
FMR LLC
Evidence rows
15
Latest as of
31 Mar 2026
13F
13D/G
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Rank 1 holder
FMR LLC
13F
13D/G
- Ownership
- 15%
- Position
- $665.38M
Rank 2 holder
Farallon Capital Partners, L.P.
13D/G
- Ownership
- 8.5%
- Position
- $373.52M
Rank 3 holder
WELLINGTON MANAGEMENT GROUP LLP
13F
13D/G
- Ownership
- 7.8%
- Position
- $374.16M
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
15%
from 13D/G
|
$665,375,245
14,293,775 shares
|
— | 31 Dec 2025 |
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
8.5%
|
$373,521,762
8,024,098 shares
|
+$111,673,450 | 31 Dec 2025 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
13D/G
Company
|
7.8%
from 13D/G
|
$374,163,733
8,037,889 shares
|
— | 31 Dec 2025 |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
13D/G
Company
|
6.1%
from 13D/G
|
$297,349,297
6,387,740 shares
|
— | 31 Dec 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
Vanguard Capital Management
|
5.2%
|
$197,604,263
5,440,646 shares
|
$0 | 31 Mar 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
13D/G
Company · T. Rowe Price Associates, Inc.
|
5.1%
from 13D/G
|
$243,196,000
5,224,387 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
239
Shares
122,775,077
Rows available
239
| Investor | Option | Weight % | Change % | Reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* Reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that failed the local validity check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
239
Q1 2026 holders
239
Holder diff
0
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend